Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Wall Street rose on Friday, setting up a strong finish to the week, after Trump's interim pick for a Fed governor post fueled expectations.

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Note that some links may require registration or subscription. The Trump administration is set to announce a proposed rule ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...